Eradicating Helicobacter pylori in adults with COPD

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a quasi-experimental interventional study at Zagazig University recruiting consecutive, well‑controlled COPD patients over six months and screening them for H. pylori using a stool antigen lateral flow test. Patients aged 40 and older who are spirometry‑confirmed COPD and H. pylori positive will receive standard eradication therapy and be followed in the outpatient and inpatient chest clinics. Baseline data including spirometry, smoking history, comorbidities, and prior exacerbations will be collected and outcomes will include exacerbation and hospitalization rates and markers of systemic inflammation. About 108 COPD patients are expected to be screened to enroll roughly 54 H. pylori‑positive participants.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged ≥40 years.
* Diagnosed with COPD confirmed by spirometry (post-bronchodilator FEV1/FVC \< 0.70) and H. pylori positive.
* Willing to participate and provide consent for testing and follow-up.

Exclusion Criteria:

* patients with asthma, known peptic ulcers, acute exacerbation of COPD
* patients who took antibiotics and PPIs within the last month,
* Patients who took histamine-2-receptor antagonists within the last week or antacid within the last 24 hours a
* those having H. pylori eradication treatment within the last 6 months

Where it's running

• Zagazig University outpatients clinics
  Zagazig, Elsharkia, Egypt Recruiting

Study contacts

• Study coordinator: Hanaa A Nofal, MD
• Email: hanofal@medicine.zu.edu.eg
• Phone: 01006806873

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Chronic Respiratory Disease Participant Engagement

  This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.

  Recruiting Richmond Pharmacology Limited · London · NCT07924462

• IOS-based platform to screen, diagnose, and manage COPD and asthma

  This study tests an Impulse Oscillometry system to screen for and diagnose COPD and asthma and to help predict flare-ups over about a year, involving adults in China.

  Recruiting Beijing Chao Yang Hospital · Beijing, Beijing Municipality · NCT07910409

• Targeted NMES to improve breathing and leg/extra muscle strength in COPD

  This study tests whether targeted neuromuscular electrical stimulation helps people with COPD see improvements in breathing muscle function and overall muscle strength.

  Recruiting Universitas Padjadjaran · Bandung, West Java · NCT07910006

• AERO-007: a inhaled LABA+LAMA combination for COPD through a nebulizer

  This study tests whether a nebulized LABA+LAMA combination can improve lung function in adults with COPD.

  Recruiting Phase 2 AeroRx Therapeutics Inc. · London and 1 other locations · NCT07896252

• PBMT with a pulmonary rehab program for COPD patients

  A small randomized trial tests whether adding photobiomodulation therapy before exercise in a COPD pulmonary rehab program helps improve functional capacity.

  Recruiting Federal University of Health Science of Porto Alegre · Porto Alegre, Rio Grande do Sul · NCT07878884

• Controlled versus standard oxygen therapy for ICU COPD with acute exacerbation

  This trial tests whether keeping oxygen levels at 88-92% helps ICU patients with an acute COPD flare more than keeping levels above 94%.

  Recruiting Hôpital Universitaire Taher Sfar · Mahdia, Mahdia Governorate and 1 other locations · NCT07842510

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.